lazertinib(YH25448) Clinical Trials (2026): 3 Studies for EGFR Gene Mutation & Lung Neoplasms
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 lazertinib(YH25448) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including EGFR Gene Mutation & Lung Neoplasms) and 288 total planned enrollment. Most recent activity: NCT05326425 (Jun 2024).
lazertinib(YH25448) clinical trials at a glance: phase × recruitment status
| Phase | completed | unknown | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 | |
| P2 | 1 | 1 |
lazertinib(YH25448) clinical trials by indication
Lung Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05326425 | — | P2 | unknown | Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03556436 | — | P1 | completed | Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 |
EGFR Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03046992 | — | P1/P2 | completed | Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC |
All lazertinib(YH25448) trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05326425 | Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. | P2 | unknown | 40 | Jin Hyoung Kang | Jun 2021 | |
| NCT03046992 | Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC | P1/P2 | completed | 224 | Yuhan Corporation | Feb 2017 | |
| NCT03556436 | Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 | P1 | completed | 24 | Yuhan Corporation | Jul 2018 |
lazertinib(YH25448) clinical trials: frequently asked questions
- How many lazertinib(YH25448) clinical trials are there?
- 3 lazertinib(YH25448) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are marked completed.
- Are lazertinib(YH25448) clinical trials recruiting in 2026?
- No active lazertinib(YH25448) trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is lazertinib(YH25448) being studied for?
- lazertinib(YH25448) is being studied for EGFR Gene Mutation, Lung Neoplasms, Non-Small Cell Lung Cancer. The trials are grouped by indication on this page.
- What phase is lazertinib(YH25448) in?
- lazertinib(YH25448) clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors lazertinib(YH25448) clinical trials?
- The lead sponsor across the most lazertinib(YH25448) trials is Yuhan Corporation, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming lazertinib(YH25448)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: